Iberdrola International BV (TG:IRBH)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Iberdrola International BV Charts. Click Here for more Iberdrola International BV Charts.](/p.php?pid=staticchart&s=TG%5EIRBH&p=8&t=15)
ImmuneRegen BioSciences Holdings Inc. Establishes Research Entity in Singapore
Biotech Company to Test for Efficacy in Treating SARS, Avian Flu, Toxic
Inhalation
SCOTTSDALE, Ariz., March 29 /PRNewswire-FirstCall/ -- IR BioSciences Holdings,
Inc. (BULLETIN BOARD: IRBH) , owner of biotechnology research and development
company ImmuneRegen BioSciences, Inc., today announced it has established a
research entity in Singapore and has created IMM BioSciences Asia, Ltd. IR
BioSciences Holdings, Inc. will license the use of its proprietary compound
Homspera through this new entity for studies on the compound's efficacy in
potentially treating adverse effects of cancer, cigarette smoking, influenza,
SARS/Avian Flu, HIV among others.
The future studies are expected to be held at research labs located at Biopolis,
a center for biomedical sciences located in close proximity to the National
University of Singapore, University Hospital and the Singapore Science Parks.
The campus currently houses many mid-size and large biotech companies, as well
as several key government agencies, publicly funded research institutes and R&D
labs.
"We chose this facility very carefully," explains Michael K. Wilhelm, CEO of
ImmuneRegen BioSciences, Inc. "This facility mirrored our needs and corporate
direction. The overall design encourages strategic assistance and fosters a
collaborative culture among the private and public research community, which is
key in any research study. We are currently working on securing the space and
should be moving ahead with our studies shortly."
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences, Inc. is a biotechnology company engaged in the research
and development of applications utilizing modified Substance P, a naturally
occurring immunomodulator. Derived from homeostatic substance P, the company
has named their proprietary compound "Homspera." The Company's initial focus is
on the continuing development of Homspera for various applications for use in
improving pulmonary function and stimulating the human immune system. For more
information, please visit the Company's website at http://www.immuneregen.com/.
History of Homspera
ImmuneRegen's patents and continued substance P research are derived from
discoveries made during research funded by the Air Force Office of Scientific
Research in the early 1990s. During this research, Dr. Mark Witten (ImmuneRegen
co-founder and acting head researcher) and his associates observed that the
exposure of animals to jet fuels resulted in pathological changes in the lung
and immune systems of those exposed. It was also observed that such exposure
resulted in depletion of substance P from the lungs of the animals. These
studies further showed that the administration of substance P may help prevent
and reverse the effects of jet fuel exposure in the lungs, as well as protect
and regenerate the immune system. The immune findings led to early research on
the treatment of exposure to acute radiation and on the possible reversal of
lung damage caused by ARDS and cigarette smoke.
Statements about the Company's future expectations, including future revenues
and earnings, and all other statements in this press release other than
historical facts, are "forward-lookingstatements" within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of
1934, and as that term is defined in the Private Securities Litigation Reform
Act of 1995. The Company intends that such forward-looking statements be
subject to the safe harbors created thereby. The Company's actual results could
differ materially from expected results as a result of a number of factors,
including the uncertainties inherent in research collaborations, clinicaltrials
and product development programs, the evaluation of potential opportunities, the
level of corporate expenditures, capital market conditions, and others set forth
in the Company's periodic report on Form 8-K as filed with the Securities and
Exchange Commission on July 7, 2003.
DATASOURCE: ImmuneRegen BioSciences, Inc.
CONTACT: media, Michelle Derden of Spelling Communications,
+1-310-477-9500, ; or investors, Tony Schor of
InvestorAwareness, +1-847-945-2222, , both for ImmuneRegen
BioSciences Holdings Inc.
Web site: http://www.immuneregen.com/